Lion Biotechnologies, (NASDAQ: LBIO) which develops cancer immunotherapies, today announced its third quarter financial results.
According to the press release, “Lion anticipates the ending cash, cash equivalents and short-term investments as of December 31, 2016, to be in excess of $164.0 million.”
CEO Dr. Maria Fardis said the following:

“Lion continues building momentum in broadening the utility of our TIL technology in new indications through internal R&D as well as with our collaborators … We are building our team to become a fully integrated immuno-oncology company.”

Read the full press release here.